Gandhinagar, 27 November 2020
Gujarat scientist Dr. Mukesh Harilal Shukla who has discovered a drug for the treatment of HIV. After 12 years, the first stage of approval has passed in India. Approved by the National Biodiversity Authority. The acceptance letter was sent by NBA Secretary Justin Mohan on November 4, 2020.
The letter written by the National Biodiversity Authority states that the approval of the IPR is appropriate to the Biodiversity Act, 2002.
Bioactive composition for the treatment of the HIV /AIDS, Method of Manufacturing and using the same” using 1) Curcuma longa 2) Ocimum sanctum 3) Cyperus rotundus has been approved by the National Biodiversity Authority, in India.
Shuklaka application was received on 17 November 2018. In which the method of production of IPR (1/9 / MUM / 200) cited on the subject given in the bioactive context for the treatment of HIV was also asked to be approved. So your medication is allowed.
What is search?
Is a bioactive compositor for the treatment of HIV / AIDS. HIV related to herbal compositions. May inhibit glycoprotein. AIDS is transmitted by glycoproteins. This medicine works to prevent it.
A pilot study was carried out to ascertain the effectiveness of the drug in AIDS patients. Voluntary clinical trials of the composition were performed in patients. Voluntary clinical trials of patients are being monitored and initiated.
Formulation in the form of a dose of 500 mg hard gelatinplus is given in a dosage schedule of 2 capsules 2 times a day for a period of 3 months. The drug is safe and also has significant efficacy in the case of diabetes mellitus. The patent application number for his invention is 1899-MUM-2008.
Approval for applying for IPR as per Section 6 of the Biological Diversity Act, 2002 read with Rule 18 of the Biological Diversity Rules, 2004 – reg. Ref: Your application in Form – III dated 17.12.2018 With reference to your application cited in reference on the subject cited above to facilitate for obtaining IPR (1899/MUM/2008) on the invention titled “Bioactive composition for the treatment of the HIV /AIDS, Method of Manufacturing and using the same” using 1) Curcuma longa 2) Ocimum sanctum 3) Cyperus rotundus has been approved by the National Biodiversity Authority subject to the conditions laid down in the agreement. In this regard, I am enclosing herewith one mutually signed stamp paper Agreement executed between National Biodiversity Authority and the applicant for the applicant’s reference and compliance. It is also to inform you that breach of the terms of agreement and provisions of the Biological Diversity Act, 2002 and Biological Diversity Rule, 2004 made thereunder will invite imposition of penalties as per Section 55, 56 & 57 of the Biological Diversity Act. 2002. Pae
December 1 is #WorldAIDSDay! Use @CDCgov’s toolkit to reach out to your community and let them know how they can get involved in the fight against HIV/AIDS and protecting the health of their community. #WAD2020 https://t.co/r5qIGTrt02 pic.twitter.com/1ioZBlk582
— CDC NPIN (@CDCNPIN) November 24, 2020
Title of the invention:Bioactive Compositioafor The Treatment Of The HIVIAIDS, Method of Manufacturing and Using The Same Abstract of the invention: The invention relates to an Anti-HIV Herbal composition consisting of 30-50% by weight of said extract of Curcuma longa, 30-50% percent by weight of said extract of Ocimum sanctum and 10-30% by weight of said extract of Cyperus rotundus, and at least one carrier. The composition of the invention is capable of treating/preventing Matrix Protein p17 and other symptoms of HIV particularly notorious glycoprotein. The formulation of the present invention is novel and inventive and has not been reported so far.
The pilot study to chck the effectiveness of the composition in the patients has been conducted. The voluntary Clinical Trials of the composition in patients has been conducted. The voluntary Clinical Trials of the patients have been observed and undertaken . The composition in dosage form of 500 mg hard gelatincapsule has been administered in dosing schedule of 2 capsules 2 times a day for duration of threc months.
HIV IN GUJARAT READ
The clinical observation for thrce months suggests further duration of course to acquire more prolific results. The drug is safe and has significant efficacy even in case of diabetes mellitus. The composition fetchedresalts with safety and eflicacy even in case of diabetes mellitus. The composition fetched results withsafety and efficaev and further without any interaction even if laken onal dring Thecomposition has pathophysiological significance with salery and etlicacy.